Project Grant R01CA309209
Award Date 7/10/26
Completion Date 6/30/31
Dollars Obligated $645K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Washington University a $641,419 Project Grant on May 7, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support clinical translation and evaluation of a novel Meitner-Auger electron (MAE) emitter-based theranostic agent for metastatic castrate-resistant prostate cancer (MCRPC). The award funds development and first-in-man clinical imaging of [77BR]BR-WC-DZ, a stable bromine-77 ligand that...
- Federal Grant Award Summary The National Cancer Institute awarded Washington University a $399,829 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2026 through June 30, 2028. This grant supports fundamental research to elucidate the mechanisms underlying ADAR1 (Adenosine Deaminase Acting on RNA 1)-regulated serine metabolism and to identify novel therapeutic opportunities targeting these metabolic vulnerabilities in triple-negative breast cancer...
- Federal Grant Award Summary Award Details: The National Cancer Institute (NCI) awarded Washington University a Project Grant of $645,414 on June 18, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394), with a project completion date of May 31, 2031. Products and Services: This award funds research translating mechanistic understanding of radiation-induced pulmonary fibrosis (RIPF) into novel clinical monitoring and treatment approaches. The project deliverables...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Washington University a $542,644 Project Grant effective April 1, 2026, through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and preclinical evaluation of radiation-guided antibody-drug conjugates (ADCs) designed to improve treatment outcomes for non-small cell lung cancer (NSCLC). The research leverages a breakthrough discovery identifying...
- Project Grant Award Summary The National Cancer Institute (NCI) awarded Washington University $562,550 through the Cancer Treatment Research program (CFDA 93.395) on July 7, 2026, to support a five-year collaborative research initiative (through July 1, 2031) focused on developing novel neoantigen-based spherical nucleic acid (SNA) immunotherapeutics for triple-negative breast cancer (TNBC). In partnership with Flashpoint Therapeutics and the Gillanders Laboratory at Washington University School...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $399,829 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop novel research models for investigating sex-based disparities in glioblastoma (GBM). The award, effective July 7, 2025 through June 30, 2027, funds the creation of investigative tools and methodologies to examine how sex chromosomes and sex hormones influence GBM phenotype, proliferation, and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Washington University a Project Grant totaling $399,829 on May 14, 2026, under the Cancer Treatment Research program (CFDA 93.395) to enhance the efficacy of neoantigen cancer vaccines. The research, conducted at the institution's St. Louis, Missouri facility through April 30, 2028, focuses on addressing the low immunogenic response of current cancer vaccine formulations by targeting Type 1 Regulatory T cells (Tr1), which...
- Federal Project Grant Award Summary Thomas Jefferson University (Sidney Kimmel Medical College) received a $646,208 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective May 1, 2026 through April 30, 2031. The award supports research investigating spatial heterogeneity of HER2 (human epidermal growth factor receptor 2) expression in luminal estrogen receptor-positive (ER+) breast cancer to identify patients at elevated...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a $155,500 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2028. The award funds research to identify and characterize mutation-induced alternative splicing (MAS) events in cancer using multi-omics data. The project leverages existing sequencing data from the Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumor Analysis...